Biotech Values

[mcbio]

AVEO - 6/5/13 restructuring CC notes

1. AVEO expects both Phase 2 CRC and TNBC studies to read out in the latter part of 2014. Astellas is supporting half of the costs of both of these studies.

2. The rationale for tivozanib in TNBC is due to the relatively high levels of hypoxia in TNBC.

3. Astellas is leading the CRC trial whereas AVEO is leading the TNBC study and also the RCC study that will report out on biomarker data later this year.

4. Astellas/AVEO are looking at similar subgroups in both the CRC and TNBC trials, which include: (a) LDH levels; (b) angiogenic ligands (tumor tissue or plasma); and (c) gene signature.

5. AVEO expects data read-out on Phase 1 expansion cohort in biomarker-defined subgroups of AV-203, the ErbB3 antibody, in 2014. BIIB has ex-U.S. rights to this drug.

6. AVEO will have further announcements on pre-clinical pipeline later this year with intention to move one drug into clinical development.